O. Adotevi, B. Vingert, L. Freyburger, P. Shrikant, Y. Lone et al., B subunit of Shiga toxin-based vaccines synergize with alphagalactosylceramide to break tolerance against self antigen and elicit antiviral immunity, Journal of Immunology, vol.179, issue.5, pp.3371-3379, 1950.
URL : https://hal.archives-ouvertes.fr/hal-00172517

N. Ahmed, V. S. Brawley, M. Hegde, C. Robertson, A. Ghazi et al., Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma, Journal of Clinical Oncology, vol.33, issue.15, pp.1688-1696, 2015.

M. Alcántara-hernández, C. Torres-zárate, G. Pérez-montesinos, F. Jurado-santacruz, M. A. Domínguez-gómez et al., , 2014.

, Overexpression of hypoxia-inducible factor 1 alpha impacts FoxP3 levels in mycosis fungoides--cutaneous T-cell lymphoma: clinical implications, International Journal of Cancer, vol.134, issue.9, pp.2136-2145

S. Anguille, E. L. Smits, E. Lion, V. F. Van-tendeloo, and Z. N. Berneman, Clinical use of dendritic cells for cancer therapy, The Lancet Oncology, vol.15, issue.7, pp.257-267, 2014.

V. Appay, C. Jandus, V. Voelter, S. Reynard, S. E. Coupland et al., New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site, Journal of Immunology, vol.177, issue.3, pp.1670-1678, 1950.

F. Aranda, A. Buqué, N. Bloy, F. Castoldi, A. Eggermont et al., Trial Watch: Adoptive cell transfer for oncological indications, Oncoimmunology, vol.4, issue.11, 2015.

F. Aranda, E. Vacchelli, A. Eggermont, J. Galon, C. Sautès-fridman et al., Trial Watch. Oncoimmunology, vol.2, issue.12, 2013.

P. Armand, A. Nagler, E. A. Weller, S. M. Devine, D. E. Avigan et al., Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial, Journal of Clinical Oncology, vol.31, issue.33, pp.4199-4206, 2013.

F. Asperti-boursin, E. Real, G. Bismuth, A. Trautmann, and E. Donnadieu, CCR7 ligands control basal T cell motility within lymph node slices in a phosphoinositide 3-kinase-independent manner, Journal of Experimental Medicine, vol.204, issue.5, pp.1167-1179, 2007.

P. Attia, G. Q. Phan, A. V. Maker, M. R. Robinson, M. M. Quezado et al., Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti-Cytotoxic T-Lymphocyte Antigen-4, Journal of Clinical Oncology, vol.23, issue.25, pp.6043-6053, 2005.

F. Avogadri, R. Zappasodi, A. Yang, S. Budhu, N. Malandro et al., Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates, Cancer Immunology Research, vol.2, issue.5, pp.448-458, 2014.


S. Azzi, J. K. Hebda, and J. Gavard, Vascular permeability and drug delivery in cancers, Frontiers in Oncology, vol.3, 2013.

N. Bacher, V. Raker, C. Hofmann, E. Graulich, M. Schwenk et al., Interferon-? suppresses cAMP to disarm human regulatory T cells, Cancer Research, vol.73, issue.18, pp.5647-5656, 2013.

C. Badoual, S. Hans, N. Merillon, C. Van-ryswick, P. Ravel et al., PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer, Cancer Research, vol.73, issue.1, pp.128-138, 2013.

C. Bailey, R. Negus, A. Morris, P. Ziprin, R. Goldin et al., Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer, Clinical & Experimental Metastasis, vol.24, issue.2, pp.121-130, 2007.

T. Bald, J. Landsberg, D. Lopez-ramos, M. Renn, N. Glodde et al., Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation, Cancer Discovery, vol.4, issue.6, pp.674-687, 2014.

J. Banchereau, A. K. Palucka, M. Dhodapkar, S. Burkeholder, N. Taquet et al., Immune and Clinical Responses in Patients with Metastatic Melanoma to CD34+ Progenitor-derived Dendritic Cell Vaccine, Cancer Research, issue.17, pp.6451-6458, 2001.

J. Banchereau and R. M. Steinman, Dendritic cells and the control of immunity, Nature, vol.392, issue.6673, pp.245-252, 1998.

D. L. Barber, E. J. Wherry, D. Masopust, B. Zhu, J. P. Allison et al., Restoring function in exhausted CD8 T cells during chronic viral infection, Nature, vol.439, issue.7077, pp.682-687, 2006.

G. L. Beatty, E. G. Chiorean, M. P. Fishman, B. Saboury, U. R. Teitelbaum et al., CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans, Science, issue.6024, pp.1612-1616, 2011.

K. E. Beck, J. A. Blansfield, K. Q. Tran, A. L. Feldman, M. S. Hughes et al., Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte-Associated Antigen 4, Journal of Clinical Oncology, vol.24, issue.15, pp.2283-2289, 2006.

M. Bellone, D. Cantarella, P. Castiglioni, M. C. Crosti, A. Ronchetti et al., Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma, Journal of Immunology, vol.165, issue.5, pp.2651-2656, 1950.

H. Benlalam, N. Labarrière, B. Linard, L. Derré, E. Diez et al., Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy, European Journal of Immunology, vol.31, issue.7, pp.2007-2015, 2001.

, , 200107.

N. Bercovici, N. Haicheur, S. Massicard, F. Vernel-pauillac, O. Adotevi et al., Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients, Journal of Immunotherapy, vol.31, issue.1, pp.101-112, 1997.

M. J. Bissell and W. C. Hines, Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression, Nature Medicine, vol.17, issue.3, pp.320-329, 2011.

N. E. Blachère, H. K. Morris, D. Braun, H. Saklani, J. P. Di-santo et al., IL-2 is required for the activation of memory CD8+ T cells via antigen crosspresentation, Journal of Immunology, vol.176, issue.12, pp.7288-7300, 1950.

S. D. Blackburn, H. Shin, W. N. Haining, T. Zou, C. J. Workman et al., Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection, Nature Immunology, vol.10, issue.1, pp.29-37, 2009.

C. Blank, I. Brown, A. C. Peterson, M. Spiotto, Y. Iwai et al., PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells, Cancer Research, vol.64, issue.3, pp.1140-1145, 2004.

N. Bloy, A. Buqué, F. Aranda, F. Castoldi, A. Eggermont et al., Trial watch: Naked and vectored DNA-based anticancer vaccines, Oncoimmunology, vol.4, issue.5, 2015.

A. Boissonnas, L. Fetler, I. S. Zeelenberg, S. Hugues, and S. Amigorena, In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor, The Journal of Experimental Medicine, vol.204, issue.2, pp.345-356, 2007.

A. Boissonnas, F. Licata, L. Poupel, S. Jacquelin, L. Fetler et al., CD8+ tumor-infiltrating T cells are trapped in the tumor-dendritic cell network, Neoplasia, issue.1, pp.85-94, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01586881

H. Bönig, U. Banning, M. Hannen, Y. M. Kim, J. Verheyen et al., Transforming growth factor-beta1 suppresses interleukin-15-mediated interferongamma production in human T lymphocytes, Scandinavian Journal of Immunology, vol.50, issue.6, pp.612-618, 1999.

B. Breart, F. Lemaître, S. Celli, and P. Bousso, Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice, Journal of Clinical Investigation, vol.118, issue.4, pp.1390-1397, 2008.

R. J. Brentjens, J. Latouche, E. Santos, F. Marti, M. C. Gong et al., Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15, Nature Medicine, vol.9, issue.3, pp.279-286, 2003.

D. G. Brooks, M. J. Trifilo, K. H. Edelmann, L. Teyton, D. B. Mcgavern et al., Interleukin-10 determines viral clearance or persistence in vivo, Nature Medicine, vol.12, issue.11, pp.1301-1309, 2006.

I. N. Buhtoiarov, P. M. Sondel, J. M. Wigginton, T. N. Buhtoiarova, E. M. Yanke et al., Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages, Immunology, vol.132, issue.2, pp.226-239, 2011.

F. M. Burnet, The concept of immunological surveillance, Progress in Experimental Tumor Research, vol.13, pp.1-27, 1970.

M. Burnet, Cancer-A Biological Approach, British Medical Journal, vol.1, issue.5022, pp.779-786, 1957.

C. Camisaschi, C. Casati, F. Rini, M. Perego, A. De-filippo et al., LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites, Journal of Immunology, vol.184, issue.11, pp.6545-6551, 1950.

H. Cann, A. , S. Netten, V. , P. et al., Dr William Coley and Tumour Regression: A Place in History or in the Future, Postgraduate Medical Journal, vol.79, issue.938, pp.672-680, 2003.

J. Carrasco, A. Van-pel, B. Neyns, B. Lethé, F. Brasseur et al., Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells, Journal of Immunology, vol.180, issue.5, pp.3585-3593, 1950.

J. C. Castle, S. Kreiter, J. Diekmann, M. Löwer, N. Van-de-roemer et al., Exploiting the mutanome for tumor vaccination, Cancer Research, vol.72, issue.5, pp.1081-1091, 2012.

C. M. Celluzzi, J. I. Mayordomo, W. J. Storkus, M. T. Lotze, and L. D. Falo, Peptidepulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity, The Journal of Experimental Medicine, vol.183, issue.1, pp.283-287, 1996.

C. Chang, J. Qiu, D. O'sullivan, M. D. Buck, T. Noguchi et al., Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression, Cell, vol.162, issue.6, pp.1229-1241, 2015.

M. Chapon, C. Randriamampita, E. Maubec, C. Badoual, S. Fouquet et al., Progressive Upregulation of PD-1 in Primary and Metastatic Melanomas Associated with Blunted TCR Signaling in Infiltrating T Lymphocytes, J Invest Dermatol, vol.131, issue.6, pp.1300-1307, 2011.

P. Chaturvedi, D. M. Gilkes, N. Takano, and G. L. Semenza, Hypoxia-inducible factordependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment, Proceedings of the National Academy of Sciences of the United States of America, vol.111, pp.2120-2129, 2014.

H. Chen, N. Tanaka, Y. Mitani, E. Oda, H. Nozawa et al., Critical role for constitutive type I interferon signaling in the prevention of cellular transformation, Cancer Science, vol.100, issue.3, pp.449-456, 2009.

H. Chen, A. Fermin, S. Vardhana, I. Weng, K. F. Lo et al., Galectin-3 negatively regulates TCR-mediated CD4+ T-cell activation at the immunological synapse, Proceedings of the National Academy of Sciences of the United States of America, vol.106, pp.14496-14501, 2009.

J. J. Chen, Y. Lin, P. Yao, A. Yuan, H. Chen et al., Tumor-associated macrophages: the double-edged sword in cancer progression, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.23, issue.5, pp.953-964, 2005.

S. Chikuma, Basics of PD-1 in self-tolerance, infection, and cancer immunity, International Journal of Clinical Oncology, 2016.

H. Cho, S. Lee, S. Seo, I. Choi, I. Choi et al., Interferon-sensitive response element (ISRE) is mainly responsible for IFN-?-induced upregulation of programmed death-1 (PD-1) in macrophages, Biochimica et Biophysica Acta (BBA) -Gene Regulatory Mechanisms, issue.12, pp.811-819, 2008.

H. C. Chong, C. K. Tan, R. Huang, and N. S. Tan, Matricellular proteins: a sticky affair with cancers, Journal of Oncology, p.351089, 2012.

E. T. Clambey, E. N. Mcnamee, J. A. Westrich, L. E. Glover, E. L. Campbell et al., Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa, Proceedings of the National Academy of Sciences of the United States of America, vol.109, issue.41, pp.2784-2793, 2012.

R. L. Coffman, A. Sher, and R. A. Seder, Vaccine Adjuvants: Putting Innate Immunity to Work, Immunity, vol.33, issue.4, pp.492-503, 2010.

W. B. Coley, II. Contribution to the Knowledge of Sarcoma, Annals of Surgery, vol.14, issue.3, pp.199-220, 1891.

C. D. Conrady, M. Zheng, N. A. Mandal, N. Van-rooijen, and D. J. Carr, IFN-?-driven CCL2 production recruits inflammatory monocytes to infection site in mice, Mucosal Immunology, vol.6, issue.1, pp.45-55, 2013.

C. A. Corzo, T. Condamine, L. Lu, M. J. Cotter, J. Youn et al., HIF-1? regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment, The Journal of Experimental Medicine, vol.207, issue.11, pp.2439-2453, 2010.

T. J. Curiel, G. Coukos, L. Zou, X. Alvarez, P. Cheng et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival, Nature Medicine, vol.10, issue.9, pp.942-949, 2004.


V. Dardalhon, A. C. Anderson, J. Karman, L. Apetoh, R. Chandwaskar et al., Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells, Journal of Immunology, vol.185, issue.3, pp.1383-1392, 1950.

M. L. Davila, I. Riviere, X. Wang, S. Bartido, J. Park et al., Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia, Science Translational Medicine, vol.6, issue.224, pp.224-249, 2014.

M. De-palma, R. Mazzieri, L. S. Politi, F. Pucci, E. Zonari et al., Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis, Cancer Cell, vol.14, issue.4, pp.299-311, 2008.


E. J. Delorme and P. Alexander, Issue 7351TREATMENT OF PRIMARY FIBROSARCOMA IN THE RAT WITH IMMUNE LYMPHOCYTES. The Lancet, vol.2, pp.117-120, 1964.

, , pp.90126-90132

O. Demaria, A. De-gassart, S. Coso, N. Gestermann, J. Di-domizio et al., STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity, Proceedings of the National Academy of Sciences of the United States of America, vol.112, pp.15408-15413, 2015.

N. Demotte, V. Stroobant, P. J. Courtoy, P. Van-der-smissen, D. Colau et al., Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes, Immunity, vol.28, issue.3, pp.414-424, 2008.

N. Demotte, G. Wieërs, P. Van-der-smissen, M. Moser, C. Schmidt et al., A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice, Cancer Research, vol.70, issue.19, pp.7476-7488, 2010.

D. G. Denardo, D. J. Brennan, E. Rexhepaj, B. Ruffell, S. L. Shiao et al., Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy, Cancer Discovery, vol.1, issue.1, pp.54-67, 2011.

B. Deng, J. Zhu, Y. Wang, T. Liu, Y. Ding et al., Intratumor hypoxia promotes immune tolerance by inducing regulatory T cells via TGF-?1 in gastric cancer, PloS One, vol.8, issue.5, 2013.

C. M. Díaz-montero, S. El-naggar, A. Al-khami, R. El-naggar, A. J. Montero et al., Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model, Cancer Immunology, Immunotherapy: CII, vol.57, issue.4, pp.563-572, 2008.

A. S. Dighe, E. Richards, L. J. Old, and R. D. Schreiber, Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors, Immunity, vol.1, issue.6, pp.447-456, 1994.

L. Dolcetti, E. Peranzoni, S. Ugel, I. Marigo, A. Fernandez-gomez et al., Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF, European Journal of Immunology, vol.40, issue.1, pp.22-35, 2010.

H. Dong, S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano et al., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nature Medicine, vol.8, issue.8, pp.793-800, 2002.

O. G. Donnelly, F. Errington-mais, L. Steele, E. Hadac, V. Jennings et al., Measles virus causes immunogenic cell death in human melanoma, Gene Therapy, vol.20, issue.1, pp.7-15, 2013.

J. Dubrot, A. Palazón, C. Alfaro, A. Azpilikueta, M. C. Ochoa et al., Intratumoral injection of interferon-? and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy, International Journal of Cancer. Journal International Du Cancer, vol.128, issue.1, pp.105-118, 2011.

J. C. Dudda, J. C. Simon, and S. Martin, Dendritic Cell Immunization Route Determines CD8+ T Cell Trafficking to Inflamed Skin: Role for Tissue Microenvironment and Dendritic Cells in Establishment of T Cell-Homing Subsets, The Journal of Immunology, vol.172, issue.2, pp.857-863, 2004.

M. E. Dudley, J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu et al., Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes, Science, vol.298, issue.5594, pp.850-854, 2002.

M. E. Dudley, J. C. Yang, R. Sherry, M. S. Hughes, R. Royal et al., Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens, Journal of Clinical Oncology, vol.26, issue.32, pp.5233-5239, 2008.

D. Dudziak, A. O. Kamphorst, G. F. Heidkamp, V. R. Buchholz, C. Trumpfheller et al., Differential antigen processing by dendritic cell subsets in vivo, Science, issue.5808, pp.107-111, 2007.


G. P. Dunn, A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber, Cancer immunoediting: from immunosurveillance to tumor escape, Nature Immunology, vol.3, issue.11, pp.991-998, 2002.

G. P. Dunn, K. C. Sheehan, L. J. Old, and R. D. Schreiber, IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression, Cancer Research, vol.65, issue.8, pp.3447-3453, 2005.

H. F. Dvorak, Tumors: wounds that do not heal-redux, Cancer Immunology Research, vol.3, issue.1, pp.1-11, 2015.

P. Ehrlich, Über den jetzigen Stand der Chemotherapie, Berichte Der Deutschen Chemischen Gesellschaft, vol.42, issue.1, pp.17-47, 1909.

M. Ejrnaes, C. M. Filippi, M. M. Martinic, E. M. Ling, L. M. Togher et al., Resolution of a chronic viral infection after interleukin-10 receptor blockade, The Journal of Experimental Medicine, vol.203, issue.11, pp.2461-2472, 2006.

A. M. Engel, I. M. Svane, S. Mouritsen, J. Rygaard, J. Clausen et al., Methylcholanthrene-induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression, Microbiologica, et Immunologica Scandinavica, vol.104, issue.9, pp.629-639, 1996.

J. J. Engelhardt, B. Boldajipour, P. Beemiller, P. Pandurangi, C. Sorensen et al., Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells, Cancer Cell, vol.21, issue.3, pp.402-417, 2012.

E. Eruslanov, M. Neuberger, I. Daurkin, G. Q. Perrin, C. Algood et al., Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer, International Journal of Cancer, vol.130, issue.5, pp.1109-1119, 2012.

L. Erwig and P. M. Henson, Clearance of apoptotic cells by phagocytes, Cell Death & Differentiation, vol.15, issue.2, pp.243-250, 2007.

A. Facciabene, X. Peng, I. S. Hagemann, K. Balint, A. Barchetti et al., Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells, Nature, vol.475, issue.7355, pp.226-230, 2011.

E. J. Foley, Antigenic Properties of Methylcholanthrene-induced Tumors in Mice of the Strain of Origin, Cancer Research, vol.13, issue.12, pp.835-837, 1953.

J. Folkman, Angiogenesis. Annual Review of Medicine, vol.57, pp.1-18, 2006.


L. Fong, D. Brockstedt, C. Benike, L. Wu, and E. G. Engleman, Dendritic Cells Injected Via Different Routes Induce Immunity in Cancer Patients, The Journal of Immunology, vol.166, issue.6, pp.4254-4259, 2001.

S. J. Forbes and N. Rosenthal, Preparing the ground for tissue regeneration: from mechanism to therapy, Nature Medicine, vol.20, issue.8, pp.857-869, 2014.

J. Fourcade, Z. Sun, M. Benallaoua, P. Guillaume, I. F. Luescher et al., Upregulation of Tim-3 and PD-1 expression is associated with tumor antigenspecific CD8+ T cell dysfunction in melanoma patients, The Journal of Experimental Medicine, vol.207, issue.10, pp.2175-2186, 2010.

M. F. Fransen, T. C. Sluis, . Van-der, F. Ossendorp, R. Arens et al., Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-CellDependent Tumor Eradication and Decreases Risk of Toxic Side Effects, Clinical Cancer Research, vol.19, issue.19, pp.5381-5389, 2013.

C. Frantz, K. M. Stewart, and V. M. Weaver, The extracellular matrix at a glance, Journal of Cell Science, vol.123, pp.4195-4200, 2010.

G. J. Freeman, A. J. Long, Y. Iwai, K. Bourque, T. Chernova et al., Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation, The Journal of Experimental Medicine, vol.192, issue.7, pp.1027-1034, 2000.

M. Frentsch, R. Stark, N. Matzmohr, S. Meier, S. Durlanik et al., CD40L expression permits CD8+ T cells to execute immunologic helper functions, Blood, vol.122, issue.3, pp.405-412, 2013.

J. Fu, I. Malm, D. K. Kadayakkara, H. Levitsky, D. Pardoll et al., Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors, Cancer Research, vol.74, issue.15, pp.4042-4052, 2014.

M. B. Fuertes, A. K. Kacha, J. Kline, S. Woo, D. M. Kranz et al., Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells, The Journal of Experimental Medicine, vol.208, issue.10, pp.2005-2016, 2011.

T. Fukumori, Y. Takenaka, T. Yoshii, H. C. Kim, V. Hogan et al., CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis, Cancer Research, vol.63, issue.23, pp.8302-8311, 2003.

D. I. Gabrilovich and S. Nagaraj, Myeloid-derived suppressor cells as regulators of the immune system, Nature Reviews. Immunology, vol.9, issue.3, pp.162-174, 2009.


G. Gautier, M. Humbert, F. Deauvieau, M. Scuiller, J. Hiscott et al., A type I interferon autocrine-paracrine loop is involved in Toll-like receptorinduced interleukin-12p70 secretion by dendritic cells, The Journal of Experimental Medicine, vol.201, issue.9, pp.1435-1446, 2005.

A. Gauvrit, S. Brandler, C. Sapede-peroz, N. Boisgerault, F. Tangy et al., Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to crossprime tumor-specific CD8 response, Cancer Research, vol.68, issue.12, pp.4882-4892, 2008.
URL : https://hal.archives-ouvertes.fr/pasteur-00330770

C. Germeau, W. Ma, F. Schiavetti, C. Lurquin, E. Henry et al., High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens, The Journal of Experimental Medicine, vol.201, issue.2, pp.241-248, 2005.

G. T. Gibney, R. R. Kudchadkar, R. C. Deconti, M. S. Thebeau, M. P. Czupryn et al., Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol.21, issue.4, pp.712-720, 2015.

D. E. Gilham, R. Debets, M. Pule, R. E. Hawkins, and H. Abken, CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe, Trends in Molecular Medicine, vol.18, issue.7, pp.377-384, 2012.

F. Ginhoux, J. L. Schultze, P. J. Murray, J. Ochando, and S. K. Biswas, New insights into the multidimensional concept of macrophage ontogeny, activation and function, Nature Immunology, vol.17, issue.1, pp.34-40, 2016.

P. Goedegebuure, J. B. Mitchem, M. R. Porembka, M. C. Tan, B. A. Belt et al., Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer, Current Cancer Drug Targets, vol.11, issue.6, pp.734-751, 2011.

L. Golden-mason, B. E. Palmer, N. Kassam, L. Townshend-bulson, S. Livingston et al., Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells, Journal of Virology, vol.83, issue.18, pp.9122-9130, 2009.

R. S. Goldszmid and G. Trinchieri, The price of immunity, Nature Immunology, vol.13, issue.10, pp.932-938, 2012.

T. S. Griffith, S. R. Wiley, M. Z. Kubin, L. M. Sedger, C. R. Maliszewski et al., Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. The Journal of Experimental Medicine, vol.189, issue.8, pp.1343-1354, 1999.

G. Gross, T. Waks, and Z. Eshhar, Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity, Proceedings of the National Academy of Sciences of the United States of America, vol.86, issue.24, pp.10024-10028, 1989.

J. Guillerme, N. Boisgerault, D. Roulois, J. Ménager, C. Combredet et al., Measles virus vaccine-infected tumor cells induce tumor antigen crosspresentation by human plasmacytoid dendritic cells, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol.19, issue.5, pp.1147-1158, 2013.

B. Guillot, P. Portalès, A. D. Thanh, S. Merlet, O. Dereure et al., The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment, The British Journal of Dermatology, vol.152, issue.4, pp.690-696, 2005.

O. A. Haabeth, K. B. Lorvik, C. Hammarström, I. M. Donaldson, G. Haraldsen et al., Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer, Nature Communications, vol.2, p.240, 2011.

N. Haicheur, E. Bismuth, S. Bosset, O. Adotevi, G. Warnier et al., The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens, Journal of Immunology, vol.165, issue.6, pp.3301-3308, 1950.

J. Hamanishi, M. Mandai, M. Iwasaki, T. Okazaki, Y. Tanaka et al., Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer, Proceedings of the National Academy of Sciences of the United States of America, vol.104, pp.3360-3365, 2007.

J. Hamanishi, M. Mandai, N. Matsumura, K. Abiko, T. Baba et al., PD-1/PD-L1 blockade in cancer treatment: perspectives and issues, International Journal of Clinical Oncology, vol.21, issue.3, pp.462-473, 2016.

D. Hanahan and R. A. Weinberg, The hallmarks of cancer, Cell, vol.100, issue.1, pp.57-70, 2000.

D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell, vol.144, issue.5, pp.646-674, 2011.

H. Harlin, Y. Meng, A. C. Peterson, Y. Zha, M. Tretiakova et al., Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment, Cancer Research, vol.69, issue.7, pp.3077-3085, 2009.

B. K. Helmich and R. W. Dutton, The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors, Journal of Immunology, vol.166, issue.11, pp.6500-6508, 1950.

R. S. Herbst, J. Soria, M. Kowanetz, G. D. Fine, O. Hamid et al., Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, vol.515, issue.7528, pp.563-567, 2014.

G. Heuff, H. S. Oldenburg, H. Boutkan, J. J. Visser, R. H. Beelen et al., Enhanced tumour growth in the rat liver after selective elimination of Kupffer cells, Cancer Immunology, Immunotherapy: CII, vol.37, issue.2, pp.125-130, 1993.

M. Heusinkveld, . Van-der, and S. H. Burg, Identification and manipulation of tumor associated macrophages in human cancers, Journal of Translational Medicine, vol.9, 2011.

B. Hinz, S. H. Phan, V. J. Thannickal, M. Prunotto, A. Desmoulière et al., Recent developments in myofibroblast biology: paradigms for connective tissue remodeling, The American Journal of Pathology, vol.180, issue.4, pp.1340-1355, 2012.

F. S. Hodi, S. J. O'day, D. F. Mcdermott, R. W. Weber, J. A. Sosman et al., Improved survival with ipilimumab in patients with metastatic melanoma, The New England Journal of Medicine, vol.363, issue.8, pp.711-723, 2010.


J. A. Hollenbaugh and R. W. Dutton, IFN-? Regulates Donor CD8 T Cell Expansion, Migration, and Leads to Apoptosis of Cells of a Solid Tumor, The Journal of Immunology, vol.177, issue.5, pp.3004-3011, 2006.

J. A. Hollenbaugh, J. Reome, M. Dobrzanski, and R. W. Dutton, The rate of the CD8-dependent initial reduction in tumor volume is not limited by contact-dependent perforin, Fas ligand, or TNF-mediated cytolysis, Journal of Immunology, vol.173, issue.3, pp.1738-1743, 1950.


A. M. Høye and J. T. Erler, Structural ECM components in the pre-metastatic and metastatic niche, American Journal of Physiology. Cell Physiology, 2016.

A. Huang, B. Zhang, B. Wang, F. Zhang, K. Fan et al., Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients, Cancer Immunology, Immunotherapy: CII, vol.62, issue.9, pp.1439-1451, 2013.

X. Huang, F. Venet, Y. L. Wang, A. Lepape, Z. Yuan et al., PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis, Proceedings of the National Academy of Sciences of the United States of America, vol.106, pp.6303-6308, 2009.

B. Huard, M. Tournier, T. Hercend, F. Triebel, and F. Faure, Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes, European Journal of Immunology, vol.24, issue.12, pp.3216-3221, 1994.

R. C. Hughes, Secretion of the galectin family of mammalian carbohydrate-binding proteins, Biochimica Et Biophysica Acta, vol.1473, issue.1, pp.172-185, 1999.

A. A. Hurwitz, T. F. Yu, D. R. Leach, and J. P. Allison, CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma, Proceedings of the, vol.95, pp.10067-10071, 1998.

K. Inaba, M. Inaba, N. Romani, H. Aya, M. Deguchi et al., Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor, The Journal of Experimental Medicine, vol.176, issue.6, pp.1693-1702, 1992.

K. Inaba, J. P. Metlay, M. T. Crowley, and R. M. Steinman, Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ, The Journal of Experimental Medicine, vol.172, issue.2, pp.631-640, 1990.

A. Isaacs and J. Lindenmann, Virus interference. I. The interferon, Proceedings of the Royal Society of London. Series B, vol.147, pp.258-267, 1957.

A. Iwasaki and R. Medzhitov, Control of adaptive immunity by the innate immune system, Nature Immunology, vol.16, issue.4, pp.343-353, 2015.

C. A. Janeway, Approaching the asymptote? Evolution and revolution in immunology, Cold Spring Harbor Symposia on Quantitative Biology, 54 Pt, vol.1, pp.1-13, 1989.

L. Johannes and W. Römer, Shiga toxins--from cell biology to biomedical applications, Nature Reviews. Microbiology, vol.8, issue.2, pp.105-116, 2010.

R. B. Jones, L. C. Ndhlovu, J. D. Barbour, P. M. Sheth, A. R. Jha et al., Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection, The Journal of Experimental Medicine, issue.12, pp.2763-2779, 2008.

H. Jonuleit, U. Kühn, G. Müller, K. Steinbrink, L. Paragnik et al., Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions, European Journal of Immunology, vol.27, issue.12, pp.3135-3142, 1997.

B. M. Kacinski, CSF-1 and its receptor in ovarian, endometrial and breast cancer, Annals of Medicine, vol.27, issue.1, pp.79-85, 1995.

A. Kaiser, N. Bercovici, J. Abastado, and A. Nardin, Naive CD8+ T cell recruitment and proliferation are dependent on stage of dendritic cell maturation, European Journal of Immunology, vol.33, issue.1, pp.162-171, 2003.

P. W. Kantoff, C. S. Higano, N. D. Shore, E. R. Berger, E. J. Small et al., Sipuleucel-T immunotherapy for castrationresistant prostate cancer, The New England Journal of Medicine, vol.363, issue.5, pp.411-422, 2010.

D. H. Kaplan, V. Shankaran, A. S. Dighe, E. Stockert, M. Aguet et al., Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice, Proceedings of the National Academy of Sciences of the United States of America, vol.95, issue.13, pp.7556-7561, 1998.

M. G. Katze, Y. He, and M. Gale, Viruses and interferon: a fight for supremacy, Nature Reviews. Immunology, vol.2, issue.9, pp.675-687, 2002.

B. Kavanagh, S. O'brien, D. Lee, Y. Hou, V. Weinberg et al., CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dosedependent fashion, Blood, vol.112, issue.4, pp.1175-1183, 2008.

Y. Kawarada, R. Ganss, N. Garbi, T. Sacher, B. Arnold et al., NK-and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides, Journal of Immunology, vol.167, issue.9, pp.5247-5253, 1950.

J. H. Kehrl, L. M. Wakefield, A. B. Roberts, S. Jakowlew, M. Alvarez-mon et al., Pillars Article: Production of Transforming Growth Factor ? by Human T Lymphocytes and Its Potential Role in the Regulation of T Cell Growth, The Journal of Immunology, vol.163, issue.7, pp.2939-2952, 1986.

M. E. Keir, S. C. Liang, I. Guleria, Y. E. Latchman, A. Qipo et al., Tissue expression of PD-L1 mediates peripheral T cell tolerance, The Journal of Experimental Medicine, vol.203, issue.4, pp.883-895, 2006.

H. W. Kessels, M. C. Wolkers, M. D. Van-den-boom, M. A. Van-den-valk, and T. N. Schumacher, Immunotherapy through TCR gene transfer, Nature Immunology, vol.2, issue.10, pp.957-961, 2001.

H. T. Khong, Q. J. Wang, and S. A. Rosenberg, Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression, Journal of Immunotherapy, vol.27, issue.3, pp.184-190, 1997.

G. Klein, H. O. Sjögren, E. Klein, and K. E. Hellström, Demonstration of Resistance against Methylcholanthreneinduced Sarcomas in the Primary Autochthonous Host, Cancer Research, vol.20, issue.11, pp.1561-1572, 1960.

D. Klysz, X. Tai, P. A. Robert, M. Craveiro, G. Cretenet et al., , 2015.

, Glutamine-dependent ?-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation, Science Signaling, vol.8, issue.396

C. M. Koebel, W. Vermi, J. B. Swann, N. Zerafa, S. J. Rodig et al., Adaptive immunity maintains occult cancer in an equilibrium state, Nature, vol.450, issue.7171, pp.903-907, 2007.

T. Kouo, L. Huang, A. B. Pucsek, M. Cao, S. Solt et al., Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells, Cancer Immunology Research, vol.3, issue.4, pp.412-423, 2015.

C. M. Kowolik, M. S. Topp, S. Gonzalez, T. Pfeiffer, S. Olivares et al., CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells, Cancer Research, vol.66, issue.22, pp.10995-11004, 2006.

S. Koyama, E. A. Akbay, Y. Y. Li, G. S. Herter-sprie, K. A. Buczkowski et al., Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints, Nature Communications, vol.7, 2016.

L. M. Kranz, M. Diken, H. Haas, S. Kreiter, C. Loquai et al., , 2016.

, Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

M. F. Krummel and J. P. Allison, CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation, The Journal of Experimental Medicine, vol.182, issue.2, pp.459-465, 1995.

H. Kumar, T. Kawai, and S. Akira, Pathogen recognition by the innate immune system, International Reviews of Immunology, vol.30, issue.1, pp.16-34, 2011.


V. Kumar and D. I. Gabrilovich, Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment, Immunology, vol.143, issue.4, pp.512-519, 2014.


V. Kumar, S. Patel, E. Tcyganov, and D. I. Gabrilovich, The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment, Trends in Immunology, vol.37, issue.3, pp.208-220, 2016.

N. Labarriere, A. Fortun, A. Bellec, A. Khammari, B. Dreno et al., A full GMP process to select and amplify epitope-specific T lymphocytes for adoptive immunotherapy of metastatic melanoma, Clinical & Developmental Immunology, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-01727317

N. Labarrière, N. Gervois, A. Bonnin, R. Bouquié, F. Jotereau et al., PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting, Cancer Immunology, Immunotherapy: CII, vol.57, issue.2, pp.185-195, 2008.

Q. Lahmar, J. Keirsse, D. Laoui, K. Movahedi, E. Van-overmeire et al., Tissue-resident versus monocyte-derived macrophages in the tumor microenvironment, Biochimica Et Biophysica Acta, vol.1865, issue.1, pp.23-34, 2016.


Y. Latchman, C. R. Wood, T. Chernova, D. Chaudhary, M. Borde et al., PD-L2 is a second ligand for PD-1 and inhibits T cell activation, Nature Immunology, vol.2, issue.3, pp.261-268, 2001.

H. M. Lazear, A. Lancaster, C. Wilkins, M. S. Suthar, A. Huang et al., IRF-3, IRF-5, and IRF-7 Coordinately Regulate the Type I IFN Response in Myeloid Dendritic Cells Downstream of MAVS Signaling, PLoS Pathogens, issue.1, p.9, 2013.


L. Bon, A. Durand, V. Kamphuis, E. Thompson, C. Bulfone-paus et al., Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming, Journal of Immunology, vol.176, issue.8, pp.4682-4689, 1950.

L. Bon, A. Etchart, N. Rossmann, C. Ashton, M. Hou et al., Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon, Nature Immunology, vol.4, issue.10, pp.1009-1015, 2003.

L. Bon, A. Tough, and D. F. , Type I interferon as a stimulus for cross-priming, Cytokine & Growth Factor Reviews, vol.19, issue.1, pp.33-40, 2008.

D. R. Leach, M. F. Krummel, and J. P. Allison, Enhancement of antitumor immunity by CTLA-4 blockade, Science, issue.5256, pp.1734-1736, 1996.

D. W. Lee, J. N. Kochenderfer, M. Stetler-stevenson, Y. K. Cui, C. Delbrook et al., T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, The Lancet, vol.385, issue.9967, pp.61403-61406, 2015.

R. S. Lee, E. Tartour, P. Van-der-bruggen, V. Vantomme, I. Joyeux et al., Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin, European Journal of Immunology, vol.28, issue.9, pp.2726-2737, 1998.

A. P. Lepique, K. R. Daghastanli, I. M. Cuccovia, and L. L. Villa, HPV16 Tumor Associated Macrophages Suppress Antitumor T Cell Responses, Clinical Cancer Research, vol.15, issue.13, pp.4391-4400, 2009.

W. J. Lesterhuis, I. J. De-vries, G. Schreibelt, A. J. Lambeck, E. H. Aarntzen et al., Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol.17, issue.17, pp.5725-5735, 2011.

K. R. Levental, H. Yu, L. Kass, J. N. Lakins, M. Egeblad et al., Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling, Cell, vol.139, issue.5, pp.891-906, 2009.

C. E. Lewis and J. W. Pollard, Distinct role of macrophages in different tumor microenvironments, Cancer Research, vol.66, issue.2, pp.605-612, 2006.

J. S. Lewis, R. J. Landers, J. C. Underwood, A. L. Harris, and C. E. Lewis, Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas, The Journal of Pathology, vol.192, issue.2, pp.150-158, 2000.

E. Y. Lin, A. V. Nguyen, R. G. Russell, and J. W. Pollard, Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy, The Journal of Experimental Medicine, vol.193, issue.6, pp.727-740, 2001.

L. Lin, J. Hou, F. Ma, P. Wang, X. Liu et al., Type I IFN inhibits innate IL-10 production in macrophages through histone deacetylase 11 by downregulating microRNA-145, Journal of Immunology, vol.191, issue.7, pp.3896-3904, 1950.

P. S. Linsley, J. Bradshaw, J. Greene, R. Peach, K. L. Bennett et al., Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement, Immunity, vol.4, issue.6, pp.535-543, 1996.

Y. Liu, IPC: Professional Type 1 Interferon-Producing Cells and Plasmacytoid Dendritic Cell Precursors, Annual Review of Immunology, vol.23, issue.1, pp.275-306, 2005.

N. J. Llosa, M. Cruise, A. Tam, E. C. Wicks, E. M. Hechenbleikner et al., The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints, Cancer Discovery, vol.5, issue.1, pp.43-51, 2015.

Y. Lou, C. Liu, G. Lizée, W. Peng, C. Xu et al., Antitumor activity mediated by CpG: the route of administration is critical, Journal of Immunotherapy, vol.34, issue.3, pp.279-288, 1997.

T. Lucas, A. Waisman, R. Ranjan, J. Roes, T. Krieg et al., Differential Roles of Macrophages in Diverse Phases of Skin Repair, The Journal of Immunology, vol.184, issue.7, pp.3964-3977, 2010.

C. Lurquin, B. Lethé, E. De-plaen, V. Corbière, I. Théate et al., Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen, The Journal of Experimental Medicine, vol.201, issue.2, pp.249-257, 2005.

J. Maher, Clinical immunotherapy of B-cell malignancy using CD19-targeted CAR T-cells, Current Gene Therapy, vol.14, issue.1, pp.35-43, 2014.

R. B. Mailliard, A. Wankowicz-kalinska, Q. Cai, A. Wesa, C. M. Hilkens et al., Cancer Research, vol.64, issue.17, pp.5934-5937, 2004.

N. Malandro, S. Budhu, N. F. Kuhn, C. Liu, J. T. Murphy et al., Clonal Abundance of Tumor-Specific CD4(+) T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion, Immunity, vol.44, issue.1, pp.179-193, 2016.


M. Malumbres and M. Barbacid, RAS oncogenes: the first 30 years, Nature Reviews. Cancer, vol.3, issue.6, pp.459-465, 2003.

F. O. Martinez and S. Gordon, The M1 and M2 paradigm of macrophage activation: time for reassessment, F1000prime Reports, vol.6, 2014.

C. J. Mcdonald, C. Erlichman, J. N. Ingle, G. A. Rosales, C. Allen et al., A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer, Breast Cancer Research and Treatment, vol.99, issue.2, pp.177-184, 2006.

F. Mcnab, K. Mayer-barber, A. Sher, A. Wack, and A. Garra, Type I interferons in infectious disease, Nature Reviews. Immunology, vol.15, issue.2, pp.87-103, 2015.


C. J. Melief, License to Kill" Reflects Joint Action of CD4 and CD8 T Cells, Clinical Cancer Research, vol.19, issue.16, pp.4295-4296, 2013.

T. R. Mempel, M. J. Pittet, K. Khazaie, W. Weninger, R. Weissleder et al., Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation, Immunity, vol.25, issue.1, pp.129-141, 2006.


C. D. Mills, K. Kincaid, J. M. Alt, M. J. Heilman, and A. M. Hill, M-1/M-2 macrophages and the Th1/Th2 paradigm, Journal of Immunology, vol.164, issue.12, pp.6166-6173, 1950.

E. K. Moon, C. Carpenito, J. Sun, L. S. Wang, V. Kapoor et al., Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor, Clinical Cancer Research, vol.17, issue.14, pp.4719-4730, 2011.

R. J. Moore, D. M. Owens, G. Stamp, C. Arnott, F. Burke et al., Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis, Nature Medicine, vol.5, issue.7, pp.828-831, 1999.

R. A. Morgan, M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang et al., Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes, Science, vol.314, issue.5796, pp.126-129, 2006.


U. Müller, U. Steinhoff, L. F. Reis, S. Hemmi, J. Pavlovic et al., Functional role of type I and type II interferons in antiviral defense, Science, issue.5167, pp.1918-1921, 1994.

G. Murphy, B. Tjoa, H. Ragde, G. Kenny, and A. Boynton, Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. The Prostate, vol.29, pp.371-380, 1996.

K. Newick, S. O'brien, J. Sun, V. Kapoor, S. Maceyko et al., Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization, Cancer Immunology Research, vol.4, issue.6, pp.541-551, 2016.


H. Nishimura, M. Nose, H. Hiai, N. Minato, and T. Honjo, Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM MotifCarrying Immunoreceptor, Immunity, vol.11, issue.2, pp.80089-80097, 1999.

H. Nishimura, T. Okazaki, Y. Tanaka, K. Nakatani, M. Hara et al., Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice, Science, issue.5502, pp.319-322, 2001.

K. Oguma, H. Oshima, M. Aoki, R. Uchio, K. Naka et al., Activated macrophages promote Wnt signalling through tumour necrosis factor-alpha in gastric tumour cells, The EMBO Journal, vol.27, issue.12, pp.1671-1681, 2008.


K. Oh, O. Lee, S. Y. Shon, O. Nam, P. M. Ryu et al., A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model, Breast Cancer Research: BCR, vol.15, issue.5, 2013.

H. Okada, P. Kalinski, R. Ueda, A. Hoji, G. Kohanbash et al., Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol.13, issue.3, pp.958-964, 2007.

S. J. Oosterling, G. J. Van-der-bij, G. A. Meijer, C. W. Tuk, E. Van-garderen et al., Macrophages direct tumour histology and clinical outcome in a colon cancer model, The Journal of Pathology, vol.207, issue.2, pp.147-155, 2005.

T. O'sullivan, R. Saddawi-konefka, W. Vermi, C. M. Koebel, C. Arthur et al., Cancer immunoediting by the innate immune system in the absence of adaptive immunity, The Journal of Experimental Medicine, vol.209, issue.10, pp.1869-1882, 2012.

H. C. Outzen, R. P. Custer, G. J. Eaton, and R. T. Prehn, Spontaneous and induced tumor incidence in germfree "nude" mice, Journal of the Reticuloendothelial Society, vol.17, issue.1, pp.1-9, 1975.

D. Padua and J. Massagué, Roles of TGFbeta in metastasis, Cell Research, vol.19, issue.1, pp.89-102, 2009.

A. K. Palucka, H. Ueno, J. Connolly, F. Kerneis-norvell, J. Blanck et al., Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity, Journal of Immunotherapy, vol.29, issue.5, pp.545-557, 1997.


Y. Pang, S. K. Gara, B. R. Achyut, Z. Li, H. H. Yan et al., TGF-? signaling in myeloid cells is required for tumor metastasis, Cancer Discovery, vol.3, issue.8, pp.936-951, 2013.

C. Papewalis, B. Jacobs, M. Wuttke, E. Ullrich, T. Baehring et al., IFN-alpha skews monocytes into CD56+-expressing dendritic cells with potent functional activities in vitro and in vivo, Journal of Immunology, vol.180, issue.3, pp.1462-1470, 1950.

A. T. Parsa, J. S. Waldron, A. Panner, C. A. Crane, I. F. Parney et al., Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma, Nature Medicine, vol.13, issue.1, pp.84-88, 2007.


C. M. Paulos, C. Wrzesinski, A. Kaiser, C. S. Hinrichs, M. Chieppa et al., Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling, The Journal of Clinical Investigation, vol.117, issue.8, pp.2197-2204, 2007.

S. Paust, L. Lu, N. Mccarty, and H. Cantor, Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease, Proceedings of the National Academy of Sciences of the United States of America, vol.101, pp.10398-10403, 2004.


V. A. Pedicord, W. Montalvo, I. M. Leiner, and J. P. Allison, Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance, Proceedings of the National Academy of Sciences of the United States of America, vol.108, pp.266-271, 2011.

K. S. Peggs, S. A. Quezada, C. A. Chambers, A. J. Korman, and J. P. Allison, Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies, The Journal of Experimental Medicine, vol.206, issue.8, pp.1717-1725, 2009.

H. Peinado, S. Lavotshkin, and D. Lyden, The secreted factors responsible for premetastatic niche formation: old sayings and new thoughts, Seminars in Cancer Biology, vol.21, issue.2, pp.139-146, 2011.

K. W. Peng, G. J. Ahmann, L. Pham, P. R. Greipp, R. Cattaneo et al., Systemic therapy of myeloma xenografts by an attenuated measles virus, Blood, vol.98, issue.7, pp.2002-2007, 2001.

K. Peng, C. J. Teneyck, E. Galanis, K. R. Kalli, L. C. Hartmann et al., Intraperitoneal therapy of ovarian cancer using an engineered measles virus, Cancer Research, vol.62, issue.16, pp.4656-4662, 2002.

E. Peranzoni, S. Zilio, I. Marigo, L. Dolcetti, P. Zanovello et al., Myeloid-derived suppressor cell heterogeneity and subset definition, Current Opinion in Immunology, vol.22, issue.2, pp.238-244, 2010.

S. Phillips, S. Chokshi, A. Riva, A. Evans, R. Williams et al., CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions, Journal of Immunology, vol.184, issue.1, pp.287-295, 1950.

L. C. Platanias, Mechanisms of type-I-and type-II-interferon-mediated signalling, Nature Reviews. Immunology, vol.5, issue.5, pp.375-386, 2005.

J. Pol, N. Bloy, A. Buqué, A. Eggermont, I. Cremer et al., Trial Watch: Peptide-based anticancer vaccines, Oncoimmunology, vol.4, issue.4, 2015.

J. Pol, A. Buqué, F. Aranda, N. Bloy, I. Cremer et al., Trial Watch-Oncolytic viruses and cancer therapy, Oncoimmunology, vol.5, issue.2, 2016.

T. Powles, J. P. Eder, G. D. Fine, F. S. Braiteh, Y. Loriot et al., MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, vol.515, issue.7528, pp.558-562, 2014.

R. T. Prehn, Perspectives on oncogenesis: does immunity stimulate or inhibit neoplasia, Journal of the Reticuloendothelial Society, vol.10, issue.1, pp.1-16, 1971.

S. J. Priceman, J. L. Sung, Z. Shaposhnik, J. B. Burton, A. X. Torres-collado et al., Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy, Blood, vol.115, issue.7, pp.1461-1471, 2010.

B. Qian, J. Li, H. Zhang, T. Kitamura, J. Zhang et al., CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis, Nature, vol.475, issue.7355, pp.222-225, 2011.

P. L. Raber, P. Thevenot, R. Sierra, D. Wyczechowska, D. Halle et al., Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways, International Journal of Cancer, vol.134, issue.12, pp.2853-2864, 2014.

A. L. Rakhmilevich, M. J. Baldeshwiler, . Van-de, T. J. Voort, M. A. Felder et al., Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects, Cancer Immunology, Immunotherapy : CII, issue.10, pp.1683-1697, 2012.

I. Rauch, M. Müller, and T. Decker, The regulation of inflammation by interferons and their STATs, JAK-STAT, vol.2, issue.1, 2013.

J. Rice, C. H. Ottensmeier, and F. K. Stevenson, DNA vaccines: precision tools for activating effective immunity against cancer, Nature Reviews Cancer, vol.8, issue.2, pp.108-120, 2008.

K. Richter, P. Agnellini, and A. Oxenius, On the role of the inhibitory receptor LAG-3 in acute and chronic LCMV infection, International Immunology, vol.22, issue.1, pp.13-23, 2010.

N. Rigamonti, G. Capuano, A. Ricupito, E. Jachetti, M. Grioni et al., Modulators of arginine metabolism do not impact on peripheral T-cell tolerance and disease progression in a model of spontaneous prostate cancer, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol.17, issue.5, pp.1012-1023, 2011.

G. A. Rizzuto, T. Merghoub, D. Hirschhorn-cymerman, C. Liu, A. M. Lesokhin et al., Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response, The Journal of Experimental Medicine, vol.206, issue.4, pp.849-866, 2009.

C. Robert, G. V. Long, B. Brady, C. Dutriaux, M. Maio et al., Nivolumab in previously untreated melanoma without BRAF mutation, The New England Journal of Medicine, vol.372, issue.4, pp.320-330, 2015.

C. Robert, L. Thomas, I. Bondarenko, S. O'day, J. Weber et al., Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma, New England Journal of Medicine, vol.364, issue.26, pp.2517-2526, 2011.

P. C. Rodriguez, A. H. Zea, K. S. Culotta, J. Zabaleta, J. B. Ochoa et al., Regulation of T cell receptor CD3zeta chain expression by L-arginine, The Journal of Biological Chemistry, vol.277, issue.24, pp.21123-21129, 2002.

E. Romano, M. Kusio-kobialka, P. G. Foukas, P. Baumgaertner, C. Meyer et al., Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients, Proceedings of the National Academy of Sciences of the United States of America, vol.112, issue.19, pp.6140-6145, 2015.

S. A. Rosenberg, P. Spiess, and R. Lafreniere, A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes, Science, issue.4770, pp.1318-1321, 1986.

Y. Rui, T. Honjo, and S. Chikuma, Programmed cell death 1 inhibits inflammatory helper T-cell development through controlling the innate immune response, Proceedings of the National Academy of Sciences of the United States of America, vol.110, pp.16073-16078, 2013.

J. H. Russell and T. J. Ley, Lymphocyte-mediated cytotoxicity, Annual Review of Immunology, vol.20, pp.323-370, 2002.

S. J. Russell, M. J. Federspiel, K. Peng, C. Tong, D. Dingli et al., Remission of disseminated cancer after systemic oncolytic virotherapy, vol.89, pp.926-933, 2014.

S. J. Russell, K. Peng, and J. C. Bell, Oncolytic virotherapy, Nature Biotechnology, vol.30, issue.7, pp.658-670, 2012.

M. Ryder, R. A. Ghossein, J. C. Ricarte-filho, J. A. Knauf, and J. A. Fagin, Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer, Endocrine-Related Cancer, vol.15, issue.4, pp.1069-1074, 2008.


J. Rygaard and C. O. Povlsen, The mouse mutant nude does not develop spontaneous tumours. An argument against immunological surveillance, Acta Pathologica Et Microbiologica Scandinavica. Section B: Microbiology and Immunology, vol.82, issue.1, pp.99-106, 1974.

E. A. Said, F. P. Dupuy, L. Trautmann, Y. Zhang, Y. Shi et al., Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection, Nature Medicine, vol.16, issue.4, pp.452-459, 2010.

H. Saji, M. Koike, T. Yamori, S. Saji, M. Seiki et al., Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma, Cancer, vol.92, issue.5, pp.1085-1091, 2001.

K. Sakuishi, L. Apetoh, J. M. Sullivan, B. R. Blazar, V. K. Kuchroo et al., Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity, The Journal of Experimental Medicine, vol.207, issue.10, pp.2187-2194, 2010.


T. P. Salazar-mather, C. A. Lewis, and C. A. Biron, Type I interferons regulate inflammatory cell trafficking and macrophage inflammatory protein 1? delivery to the liver, The Journal of Clinical Investigation, vol.110, issue.3, pp.321-330, 2002.

F. Sallusto and A. Lanzavecchia, Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha, The Journal of Experimental Medicine, vol.179, issue.4, pp.1109-1118, 1994.

H. Salmon, K. Franciszkiewicz, D. Damotte, M. Dieu-nosjean, P. Validire et al., Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors, The Journal of Clinical Investigation, vol.122, issue.3, pp.899-910, 2012.

F. Sandoval, M. Terme, M. Nizard, C. Badoual, M. Bureau et al., Mucosal imprinting of vaccine-induced CD8, 2013.

, + T cells is crucial to inhibit the growth of mucosal tumors, Science Translational Medicine, vol.5, issue.172, pp.172-192

L. Sanz, B. Blanco, and L. Alvarez-vallina, Antibodies and gene therapy: teaching old "magic bullets" new tricks, Trends in Immunology, vol.25, issue.2, pp.85-91, 2004.


A. A. Sarnaik, B. Yu, D. Yu, D. Morelli, M. Hall et al., Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol.17, issue.4, pp.896-906, 2011.

D. Sauce, J. R. Almeida, M. Larsen, L. Haro, B. Autran et al., PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status, AIDS, vol.21, issue.15, pp.2005-2013, 2007.


Y. Sawada, T. Yoshikawa, M. Shimomura, T. Iwama, I. Endo et al., Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes, International Journal of Oncology, vol.46, issue.1, pp.28-36, 2015.

M. J. Scanlan, S. Welt, C. M. Gordon, Y. Chen, A. O. Gure et al., Cancer-related Serological Recognition of Human Colon Cancer Identification of Potential Diagnostic and Immunotherapeutic Targets, Cancer Research, vol.62, issue.14, pp.4041-4047, 2002.

D. Schadendorf, F. S. Hodi, C. Robert, J. S. Weber, K. Margolin et al., Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.33, issue.17, pp.1889-1894, 2015.

N. E. Scharping, A. V. Menk, R. S. Moreci, R. D. Whetstone, R. E. Dadey et al., The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction, Immunity, vol.45, issue.2, pp.374-388, 2016.

G. Schiavoni, A. Sistigu, M. Valentini, F. Mattei, P. Sestili et al., Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis, Cancer Research, vol.71, issue.3, pp.768-778, 2011.

K. G. Schmetterer, A. Neunkirchner, and W. F. Pickl, Naturally occurring regulatory T cells: markers, mechanisms, and manipulation, FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, vol.26, issue.6, pp.2253-2276, 2012.

U. Schneider, V. Von-messling, P. Devaux, and R. Cattaneo, Efficiency of measles virus entry and dissemination through different receptors, Journal of Virology, vol.76, issue.15, pp.7460-7467, 2002.

M. W. Schreurs, A. J. Boer, . De, C. G. Figdor, and G. J. Adema, Genetic Vaccination against the Melanocyte Lineage-specific Antigen gp100 Induces Cytotoxic T Lymphocyte-mediated Tumor Protection, Cancer Research, vol.58, issue.12, pp.2509-2514, 1998.

M. J. Selby, J. J. Engelhardt, M. Quigley, K. A. Henning, T. Chen et al., Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells, Cancer Immunology Research, vol.1, issue.1, pp.32-42, 2013.

V. Shankaran, H. Ikeda, A. T. Bruce, J. M. White, P. E. Swanson et al., IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity, Nature, issue.6832, pp.1107-1111, 2001.


B. Sheu, S. Chiou, H. Lin, S. Chow, S. Huang et al., Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma, Cancer Research, vol.65, issue.7, pp.2921-2929, 2005.


M. Shi, S. Hao, T. Chan, and J. Xiang, CD4+ T cells stimulate memory CD8+ T cell expansion via acquired pMHC I complexes and costimulatory molecules, and IL-2 secretion, Journal of Leukocyte Biology, vol.80, issue.6, pp.1354-1363, 2006.


H. Shime, M. Matsumoto, H. Oshiumi, S. Tanaka, A. Nakane et al., Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors, Proceedings of the National Academy of Sciences, vol.109, issue.6, pp.2066-2071, 2012.

H. Shirota, L. Petrenko, C. Hong, and D. M. Klinman, Potential of Transfected Muscle Cells to Contribute to DNA Vaccine Immunogenicity, The Journal of Immunology, vol.179, issue.1, pp.329-336, 2007.

T. R. Simpson, F. Li, W. Montalvo-ortiz, M. A. Sepulveda, K. Bergerhoff et al., Fc-dependent depletion of tumor-infiltrating regulatory T cells codefines the efficacy of anti-CTLA-4 therapy against melanoma, The Journal of Experimental Medicine, vol.210, issue.9, pp.1695-1710, 2013.

M. J. Smyth, S. L. Strobl, H. A. Young, J. R. Ortaldo, and A. C. Ochoa, Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta, Journal of Immunology, vol.146, issue.10, pp.3289-3297, 1950.

M. J. Smyth, K. Y. Thia, S. E. Street, E. Cretney, J. A. Trapani et al., Differential tumor surveillance by natural killer (NK) and NKT cells, The Journal of Experimental Medicine, vol.191, issue.4, pp.661-668, 2000.

M. J. Smyth, K. Y. Thia, S. E. Street, D. Macgregor, D. I. Godfrey et al., Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma, The Journal of Experimental Medicine, vol.192, issue.5, pp.755-760, 2000.

K. C. Soares, A. A. Rucki, A. A. Wu, K. Olino, Q. Xiao et al., PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors, Journal of Immunotherapy, vol.38, issue.1, pp.1-11, 1997.

D. A. Spandidos and M. L. Anderson, Oncogenes and onco-suppressor genes: their involvement in cancer, The Journal of Pathology, vol.157, issue.1, pp.1-10, 1989.


S. Spranger, R. M. Spaapen, Y. Zha, J. Williams, Y. Meng et al., Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells, Science Translational Medicine, vol.5, 0200.

M. K. Srivastava, L. Zhu, M. Harris-white, U. K. Kar, U. Kar et al., Myeloid suppressor cell depletion augments antitumor activity in lung cancer, PloS One, vol.7, issue.7, 2012.

S. Srivastava, M. A. Koch, M. Pepper, and D. J. Campbell, Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection, The Journal of Experimental Medicine, vol.211, issue.5, pp.961-974, 2014.


N. Stern-ginossar, C. Gur, M. Biton, E. Horwitz, M. Elboim et al., Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D, Nature Immunology, vol.9, issue.9, pp.1065-1073, 2008.


M. D. Sternlicht, A. Lochter, C. J. Sympson, B. Huey, J. Rougier et al., The Stromal Proteinase MMP3/Stromelysin-1 Promotes Mammary Carcinogenesis, Cell, vol.98, issue.2, pp.137-146, 1999.

T. Straetemans, C. Berrevoets, M. Coccoris, E. Treffers-westerlaken, R. Wijers et al., Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment, Molecular Therapy: The Journal of the American Society of Gene Therapy, vol.23, issue.2, pp.396-406, 2015.

K. Strebhardt and A. Ullrich, Paul Ehrlich's magic bullet concept: 100 years of progress, Nature Reviews Cancer, vol.8, issue.6, pp.473-480, 2008.

S. E. Street, J. A. Trapani, D. Macgregor, and M. J. Smyth, Suppression of lymphoma and epithelial malignancies effected by interferon gamma, The Journal of Experimental Medicine, vol.196, issue.1, pp.129-134, 2002.

S. E. Street, E. Cretney, and M. J. Smyth, Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis, Blood, vol.97, issue.1, pp.192-197, 2001.

I. M. Stromnes, J. S. Brockenbrough, K. Izeradjene, M. A. Carlson, C. Cuevas et al., Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity, Gut, vol.63, issue.11, pp.1769-1781, 2014.

O. Stutman, Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice, Science, issue.4124, pp.534-536, 1974.

H. Sultan, V. I. Fesenkova, D. Addis, A. E. Fan, T. Kumai et al., Designing therapeutic cancer vaccines by mimicking viral infections, Cancer Immunology, 2016.

J. Sunshine and J. M. Taube, PD-1/PD-L1 inhibitors, Current Opinion in Pharmacology, vol.23, pp.32-38, 2015.

S. L. Swain, K. K. Mckinstry, and T. M. Strutt, Expanding roles for CD4 + T cells in immunity to viruses, Nature Reviews. Immunology, vol.12, issue.2, pp.136-148, 2012.


J. B. Swann, M. D. Vesely, A. Silva, J. Sharkey, S. Akira et al., Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis, Proceedings of the National Academy of Sciences of the United States of America, vol.105, pp.652-656, 2008.

H. Takahashi, F. Feuerhake, J. L. Kutok, S. Monti, P. Dal-cin et al., FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol.12, issue.11, pp.3265-3271, 2006.

J. E. Talmadge and D. I. Gabrilovich, History of myeloid-derived suppressor cells, Nature Reviews. Cancer, vol.13, issue.10, pp.739-752, 2013.

M. Tania, M. A. Khan, and J. Fu, Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer, Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine, vol.35, issue.8, pp.7335-7342, 2014.


E. Tartour, H. Pere, B. Maillere, M. Terme, N. Merillon et al., Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy, Cancer Metastasis Reviews, vol.30, issue.1, pp.83-95, 2011.

J. M. Taube, R. A. Anders, G. D. Young, H. Xu, R. Sharma et al., Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape, Science Translational Medicine, vol.4, issue.127, pp.127-164, 2012.


J. M. Taube, A. Klein, J. R. Brahmer, H. Xu, X. Pan et al., Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy, Clinical Cancer Research, vol.20, issue.19, pp.5064-5074, 2014.

J. M. Taube, G. D. Young, T. L. Mcmiller, S. Chen, J. T. Salas et al., Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol.21, issue.17, pp.3969-3976, 2015.

B. A. Teicher, Malignant cells, directors of the malignant process: role of transforming growth factor-beta, Cancer Metastasis Reviews, vol.20, issue.1-2, pp.133-143, 2001.

S. Terawaki, S. Chikuma, S. Shibayama, T. Hayashi, T. Yoshida et al., IFN-? Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity, The Journal of Immunology, vol.186, issue.5, pp.2772-2779, 2011.

A. Textor, J. J. Listopad, L. L. Wührmann, C. Perez, A. Kruschinski et al., Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFN?, Cancer Research, vol.74, issue.23, pp.6796-6805, 2014.

L. Thomas, Cellular and Humoral Aspects of Hypersensitivity States, pp.529-532, 1959.

R. H. Thompson, M. D. Gillett, J. C. Cheville, C. M. Lohse, H. Dong et al., Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target, Proceedings of the National Academy of Sciences of the United States of America, vol.101, issue.49, pp.17174-17179, 2004.


M. Thoreau, N. Bercovici, and A. Trautmann, The vaccination-induced cooperation of T cells and myeloid cells leads to an anti-tumoral effect, 2016.

, Médecine Sciences: M/S, vol.32, pp.244-246

M. Thoreau, H. L. Penny, K. Tan, F. Regnier, J. M. Weiss et al., Vaccine-induced tumor regression requires a dynamic cooperation between T cells and myeloid cells at the tumor site, Oncotarget, vol.6, issue.29, pp.27832-27846, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01214610


R. Tinoco, V. Alcalde, Y. Yang, K. Sauer, and E. I. Zuniga, Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo, Immunity, vol.31, issue.1, pp.145-157, 2009.


B. Toh, X. Wang, J. Keeble, W. J. Sim, K. Khoo et al., Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor, PLoS Biology, vol.9, issue.9, 2011.

L. Trautmann, L. Janbazian, N. Chomont, E. A. Said, S. Gimmig et al., Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction, Nature Medicine, vol.12, issue.10, pp.1198-1202, 2006.


P. Tripathi and S. Agrawal, Non-classical HLA-G antigen and its role in the cancer progression, Cancer Investigation, vol.24, issue.2, pp.178-186, 2006.


M. Tschurtschenthaler, J. Wang, C. Fricke, T. M. Fritz, L. Niederreiter et al., Type I interferon signalling in the intestinal epithelium affects Paneth cells, microbial ecology and epithelial regeneration, Gut, vol.63, issue.12, pp.1921-1931, 2014.

P. C. Tumeh, C. L. Harview, J. H. Yearley, I. P. Shintaku, E. J. Taylor et al., PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.515, issue.7528, pp.568-571, 2014.

S. Uderhardt, M. Herrmann, O. V. Oskolkova, S. Aschermann, W. Bicker et al., 12/15-Lipoxygenase Orchestrates the Clearance of Apoptotic Cells and Maintains Immunologic Tolerance, Immunity, vol.36, issue.5, pp.834-846, 2012.


J. B. Ulmer, J. J. Donnelly, S. E. Parker, G. H. Rhodes, P. L. Felgner et al., Heterologous protection against influenza by injection of DNA encoding a viral protein, Science, issue.5102, pp.1745-1749, 1993.

E. Vacchelli, J. Pol, N. Bloy, A. Eggermont, I. Cremer et al., Trial watch: Tumor-targeting monoclonal antibodies for oncological indications, Oncoimmunology, issue.1, p.4, 2015.

P. Van-der-bruggen, C. Traversari, P. Chomez, C. Lurquin, E. De-plaen et al., A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma, Science, issue.5038, pp.1643-1647, 1991.

S. J. Van-der-stegen, D. M. Davies, S. Wilkie, J. Foster, J. K. Sosabowski et al., Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity, Journal of Immunology, vol.191, issue.9, pp.4589-4598, 1950.


A. Van-elsas, A. A. Hurwitz, and J. P. Allison, Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation, The Journal of Experimental Medicine, vol.190, issue.3, pp.355-366, 1999.

N. Van-rooij, M. M. Van-buuren, D. Philips, A. Velds, M. Toebes et al., Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.31, issue.32, pp.439-442, 2013.


R. D. Vicetti-miguel, T. L. Cherpes, L. J. Watson, and K. C. Mckenna, CTL induction of tumoricidal nitric oxide production by intratumoral macrophages is critical for tumor elimination, Journal of Immunology, vol.185, issue.11, pp.6706-6718, 1950.

N. Vigneron, V. Stroobant, B. J. Van-den-eynde, and P. Van-der-bruggen, Database of T cell-defined human tumor antigens: the 2013 update, Cancer Immunity, vol.13, 2013.

B. Vingert, O. Adotevi, D. Patin, S. Jung, P. Shrikant et al., The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity, European Journal of Immunology, vol.36, issue.5, pp.1124-1135, 2006.


K. Vopenkova, K. Mollova, I. Buresova, and J. Michalek, Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy, Journal of Cellular and Molecular Medicine, vol.16, issue.11, pp.2827-2837, 2012.

S. Wada, C. M. Jackson, K. Yoshimura, H. Yen, D. Getnet et al., Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer, Journal of Translational Medicine, vol.11, 2013.

L. S. Walker and D. M. Sansom, Confusing signals: recent progress in CTLA-4 biology, Trends in Immunology, vol.36, issue.2, pp.63-70, 2015.

T. L. Walunas, D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman et al., CTLA-4 can function as a negative regulator of T cell activation, Immunity, vol.1, issue.5, pp.405-413, 1994.

S. Wang, S. Fouquet, M. Chapon, H. Salmon, F. Regnier et al., Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors, PloS One, vol.6, issue.3, 2011.

W. Wang, R. Lau, D. Yu, W. Zhu, A. Korman et al., PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells, International Immunology, vol.21, issue.9, pp.1065-1077, 2009.

P. Waterhouse, J. M. Penninger, E. Timms, A. Wakeham, A. Shahinian et al., Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4, Science, issue.5238, pp.985-988, 1995.

J. S. Weber, R. R. Kudchadkar, B. Yu, D. Gallenstein, C. E. Horak et al., Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumabrefractory or -naive melanoma, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.31, issue.34, pp.4311-4318, 2013.

E. J. Wherry, T cell exhaustion, Nature Immunology, vol.12, issue.6, pp.492-499, 2011.

T. L. Whiteside, Induced regulatory T cells in inhibitory microenvironments created by cancer, Expert Opinion on Biological Therapy, vol.14, issue.10, pp.1411-1425, 2014.


T. L. Whiteside, Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression?, Cancer Immunology, Immunotherapy: CII, vol.63, issue.1, pp.67-72, 2014.

K. Wolf, S. Alexander, V. Schacht, L. M. Coussens, U. H. Von-andrian et al., Collagen-based cell migration models in vitro and in vivo, Seminars in Cell & Developmental Biology, vol.20, issue.8, pp.931-941, 2009.


J. A. Wolff, R. W. Malone, P. Williams, W. Chong, G. Acsadi et al., Direct gene transfer into mouse muscle in vivo, Science, issue.4949, pp.1465-1468, 1990.

C. J. Workman, L. S. Cauley, I. Kim, M. A. Blackman, D. L. Woodland et al., Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo, Journal of Immunology, vol.172, issue.9, pp.5450-5455, 1950.

S. H. Wrzesinski, Y. Y. Wan, and R. A. Flavell, Transforming growth factor-beta and the immune response: implications for anticancer therapy, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol.13, issue.18, pp.5262-5270, 2007.

Q. Xiao and G. Ge, Lysyl oxidase, extracellular matrix remodeling and cancer metastasis, Cancer Microenvironment: Official Journal of the International Cancer Microenvironment Society, vol.5, issue.3, pp.261-273, 2012.

J. Xue, S. V. Schmidt, J. Sander, A. Draffehn, W. Krebs et al., Transcriptome-based network analysis reveals a spectrum model of human macrophage activation, Immunity, vol.40, issue.2, pp.274-288, 2014.

R. Yamasaki, H. Lu, O. Butovsky, N. Ohno, A. M. Rietsch et al., Differential roles of microglia and monocytes in the inflamed central nervous system, The Journal of Experimental Medicine, vol.211, issue.8, pp.1533-1549, 2014.


J. Yan, D. K. Reichenbach, N. Corbitt, D. Hokey, M. P. Ramanathan et al., Induction of Antitumor Immunity In vivo Following Delivery of a Novel HPV-16 DNA Vaccine Encoding an E6/E7 Fusion antigen, Vaccine, vol.27, issue.3, pp.431-440, 2009.

L. Yang, J. Huang, X. Ren, A. E. Gorska, A. Chytil et al., Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis, Cancer Cell, vol.13, issue.1, pp.23-35, 2008.


Z. Yang, D. M. Grote, S. C. Ziesmer, T. Niki, M. Hirashima et al., IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma, The Journal of Clinical Investigation, vol.122, issue.4, pp.1271-1282, 2012.

T. Yokosuka, M. Takamatsu, W. Kobayashi-imanishi, A. Hashimoto-tane, M. Azuma et al., Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2, The Journal of Experimental Medicine, vol.209, issue.6, pp.1201-1217, 2012.

J. Yu, W. Du, F. Yan, Y. Wang, H. Li et al., Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer, Journal of Immunology, vol.190, issue.7, pp.3783-3797, 1950.

A. J. Zajac, J. N. Blattman, K. Murali-krishna, D. J. Sourdive, M. Suresh et al., Viral immune evasion due to persistence of activated T cells without effector function, The Journal of Experimental Medicine, vol.188, issue.12, pp.2205-2213, 1998.

Q. Zhou, M. E. Munger, R. G. Veenstra, B. J. Weigel, M. Hirashima et al., Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia, Blood, vol.117, issue.17, pp.4501-4510, 2011.

X. Zhu, J. Zhang, P. Zhuang, H. Zhu, W. Zhang et al., High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.26, issue.16, pp.2707-2716, 2008.

A. Zippelius, P. Batard, V. Rubio-godoy, G. Bioley, D. Liénard et al., Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance, Cancer Research, vol.64, issue.8, pp.2865-2873, 2004.

L. Zitvogel, J. I. Mayordomo, T. Tjandrawan, A. B. Deleo, M. R. Clarke et al., Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines, The Journal of Experimental Medicine, vol.183, issue.1, pp.87-97, 1996.

S. Zwaveling, S. C. Mota, J. Nouta, M. Johnson, G. B. Lipford et al., Established Human Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated Following Vaccination with Long Peptides, The Journal of Immunology, vol.169, issue.1, pp.350-358, 2002.